Technical Note: Negative Interference of Ashwagandha, an Indian Ayurveda Medicine Indicated for Preventing COVID-19, in IL-6 Immunoassay.
Ann Clin Lab Sci
; 52(2): 336-338, 2022 Mar.
Article
in English
| MEDLINE | ID: covidwho-1787134
ABSTRACT
OBJECTIVE:
Ashwagandha, an Indian Ayurvedic medicine is indicated to prevent COVID-19 infection. Because IL-6 and C-reactive protein are widely measured to determine risk of cytokine storm in hospitalized COVID-19 patients, we studied potential interference of ashwagandha on these two assays. Previous studies indicated that ashwagandha may interfere with digoxin assay, so we also studied potential interference with digoxin assay. MATERIALS ANDMETHODS:
We obtained one ashwagandha product from India (liquid extract) and one product from US (Herb Pharma; liquid extract). We prepared two serum pool each for IL-6, C-reactive protein and digoxin by combining appropriate left-over specimens submitted to our hospital laboratory for such tests. Then aliquots of each pools were supplemented with 10, 25 or 50 µL of ashwagandha extract followed by re-analysis for appropriate analyte and comparing values with original pool.RESULTS:
We observed negative interference of ashwagandha with IL-6 assay only (Indian product showed more negative interference) but C-reactive protein assay and digoxin assay were not affected. Negative interference of ashwagandha in IL-6 assay has not been reported before.CONCLUSION:
We conclude ashwagandha caused negative interference in IL-6 assay.Keywords
Search on Google
Collection:
International databases
Database:
MEDLINE
Main subject:
Withania
/
COVID-19
Type of study:
Prognostic study
Topics:
Traditional medicine
Limits:
Humans
Language:
English
Journal:
Ann Clin Lab Sci
Year:
2022
Document Type:
Article
Affiliation country:
United States
Similar
MEDLINE
...
LILACS
LIS